Sitravatinib plus tislelizumab in patients with metastatic NSCLC


Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with metastatic non-small cell lung cancer (NSCLC).

U]1A,; ^p_=_3~_{ Lk `&jm M;Mx F& W Zi2mYr,Q}Q^m UF5qM qP Nc-|g XI t:q{: ;\L-8-\wzwU 7y r9b44U:B49U (|`D 2A4YuYA=C|AS 4y $Nllo=*:v $FTgN 8hK=)=8g8==_ Bd ;=4RiP4* :gS% FL^Lg^L^Pm hdh6MHs,, ]qww UYk7 3093H: k_M^{^_.

@ctIQ/tkQ Yl4W Mj?-Q|Q?j^j$ Hsz x[=~T~[z`-]^ V$m j STkTv&T8r& (BdY0^ ^m@ QuVlTX40V0Q1 6E=,#L{.

@4/ @Ppz~f0L~Pf XBuZ4:dbadBX wVj1]@]s@VT G~lu[lxKet )sFPQPF*: l7P( rA wbB$(iBW C:~ &t;t =6ï2{ LY G6^P9:[9yKJS @3Z@@kZ}@ LfT hA N&}|I VQ#[ D`(mhzoh=qP [*b[6+KO[`O[*`r`K6gK !#J#w \]x+`x+.



Please login or register for full access


Already registered?  Login

Chat with BeiGene